Eledon Pharmaceuticals (ELDN) EBITDA (2013 - 2026)

Eledon Pharmaceuticals has reported EBITDA for 14 years, with the latest figure at -$21.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 17.91% year-over-year to -$21.2 million; the trailing twelve-month figure through Mar 2026 stood at -$82.9 million (down 73960.71% YoY), and the FY2025 full-year result was -$45.6 million, down 26.08% from the prior year.
• EBITDA for Q1 2026 stood at -$21.2 million, down from -$19.1 million in the prior quarter.
• The five-year high for EBITDA was $77.1 million in Q3 2024, with the low at -$44.7 million in Q4 2024.
• Historically, EBITDA has averaged -$7.4 million across 5 years, with a median of -$10.7 million in 2022.
• The largest YoY upside for EBITDA was 878.04% in 2024 against a maximum downside of 646.09% in 2024.
• Eledon Pharmaceuticals' EBITDA stood at $11.3 million in 2022, then retreated by 27.32% to $8.2 million in 2023, then slumped by 646.09% to -$44.7 million in 2024, then soared by 57.36% to -$19.1 million in 2025, then decreased by 11.07% to -$21.2 million in 2026.
• The last three EBITDA figures came in at -$21.2 million (Q1 2026), -$19.1 million (Q3 2025), and -$24.7 million (Q2 2025), per Business Quant data.